Drug Type Small molecule drug |
Synonyms O-demethyl-tramadol, O-desmethyl-tramadol, O-DSMT + [4] |
Target |
Action inhibitors, agonists |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), μ opioid receptor agonists(Mu opioid receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H23NO2 |
InChIKeyUWJUQVWARXYRCG-UYWMCZCJSA-N |
CAS Registry80456-81-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Desmetramadol | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Pain | Phase 2 | United States | 15 Nov 2018 | |
| Diabetic Neuropathies | Phase 2 | United States | 15 Nov 2018 | |
| Neuralgia | Phase 2 | United States | 15 Nov 2018 | |
| Drug Metabolism, Poor, CYP2D6-Related | Phase 1 | United States | 31 Oct 2017 |
Phase 1 | 24 | (Desmetramadol 10 mg, Fasted) | wdhtqzoquy(yebucyadfr) = nitwaomehc vkcpyglkqa (raawyuvbvz, 30.5) View more | - | 04 Apr 2023 | ||
(Desmetramadol 20 mg, Fasted) | wdhtqzoquy(yebucyadfr) = jifzvsjnhs vkcpyglkqa (raawyuvbvz, 61.3) View more |





